ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1

Jordina Rincon-Torroella,Marco Dal Molin,Brian Mog,Gyuri Han,Evangeline Watson,Nicolas Wyhs,Shun Ishiyama,Taha Ahmedna,Il Minn,Nilofer S Azad,Chetan Bettegowda,Nickolas Papadopoulos,Kenneth W Kinzler,Shibin Zhou,Bert Vogelstein,Kathleen L Gabrielson,Surojit Sur

DOI: https://doi.org/10.1101/2023.07.23.550207

2024-07-29

Abstract:Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression of Monocarboxylate Transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in clinical trials. In this study we present an alternative approach using 3-Bromopyruvate (3BP) to target MCT1 overexpressing PDACs. 3BP is a cytotoxic agent that is known to be transported into cells via MCT1, but its clinical usefulness has been hampered by difficulties in delivering the drug systemically. We describe here a novel microencapsulated formulation of 3BP (ME3BP-7), that is effective against a variety of PDAC cells in vitro and remains stable in serum. Furthermore, systemically administered ME3BP-7 significantly reduces pancreatic cancer growth and metastatic spread in multiple orthotopic models of pancreatic cancer with manageable toxicity. ME3BP-7 is, therefore, a prototype of a promising new drug, in which the targeting moiety and the cytotoxic moiety are both contained within the same single small molecule.

Cancer Biology

What problem does this paper attempt to address?

The paper attempts to address the problem of developing a novel chemotherapeutic agent, ME3BP-7, for the effective treatment of pancreatic ductal adenocarcinoma (PDAC) with high expression of monocarboxylate transporter 1 (MCT1). Although MCT1 is significantly overexpressed in approximately 30% of PDACs, existing small molecule inhibitors of MCT1 have failed to achieve success in clinical trials. 3-Bromopyruvate (3BP) is a known cytotoxic agent that enters cells via MCT1, but its clinical application is limited due to delivery challenges in vivo, particularly its rapid degradation in serum. Therefore, researchers have developed a new microencapsulated 3BP formulation (ME3BP-7) aimed at improving the stability and delivery efficiency of 3BP, thereby effectively killing PDAC cells with high MCT1 expression and reducing toxicity to normal tissues.

Specifically, the goals of the paper include:
1. **Improving the stability of 3BP**: Using microencapsulation technology to protect 3BP from protein degradation in serum, thereby extending its active time in vivo.
2. **Enhancing the cytotoxicity of 3BP**: Ensuring that ME3BP-7 can specifically target and kill PDAC cells with high MCT1 expression.
3. **Evaluating the in vivo efficacy of ME3BP-7**: Using mouse models to verify the anti-tumor effects and safety of ME3BP-7 in vivo.

In summary, this study aims to develop a new therapy targeting high MCT1-expressing PDAC by optimizing the delivery method of 3BP, thereby overcoming the limitations of existing treatment methods.